Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report

Paolo Solidoro; Stefania Nicola; Irene Ridolfi; Caterina Bucca; Enrico Heffler; Diego Bagnasco; Giorgio Walter Canonica; Francesco Blasi; Pierluigi Paggiaro; Giovanni Rolla; Luisa Brussino

doi:10.1016/j.jaip.2021.04.011

Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report

Paolo Solidoro, Stefania Nicola, Irene Ridolfi, Caterina Bucca, Enrico Heffler, Diego Bagnasco, Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Giovanni Rolla, Luisa Brussino

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2920-2922.e2
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	9
Issue number	7
DOIs	https://doi.org/10.1016/j.jaip.2021.04.011
Publication status	Published - 2021

ASJC Scopus subject areas

Immunology and Allergy

Access to Document

10.1016/j.jaip.2021.04.011

Cite this

Solidoro, P., Nicola, S., Ridolfi, I., Bucca, C., Heffler, E., Bagnasco, D., Canonica, G. W., Blasi, F., Paggiaro, P., Rolla, G., & Brussino, L. (2021). Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report. Journal of Allergy and Clinical Immunology: In Practice, 9(7), 2920-2922.e2. https://doi.org/10.1016/j.jaip.2021.04.011

Solidoro, P, Nicola, S, Ridolfi, I, Bucca, C, Heffler, E, Bagnasco, D, Canonica, GW , Blasi, F, Paggiaro, P, Rolla, G & Brussino, L 2021, 'Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report', Journal of Allergy and Clinical Immunology: In Practice, vol. 9, no. 7, pp. 2920-2922.e2. https://doi.org/10.1016/j.jaip.2021.04.011

@article{5df68956216943d1a3bf290794694299,

title = "Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report",

author = "Paolo Solidoro and Stefania Nicola and Irene Ridolfi and Caterina Bucca and Enrico Heffler and Diego Bagnasco and Canonica, {Giorgio Walter} and Francesco Blasi and Pierluigi Paggiaro and Giovanni Rolla and Luisa Brussino",

note = "Funding Information: Conflicts of interest: E. Heffler reports participation to advisory boards and personal fees from AstraZeneca, Sanofi, GSK, Novartis, Circassia, Nestl? Purina, Boheringer Ingheleim, and Valeas, outside the submitted work. G. W. Canonica reports grants as well as lecture or advisory board fees from A. Menarini, Alk-Abello, Allergy Therapeutics, AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, Glaxo Smith Kline, Hal Allergy, Mylan, Merck, Mundipharma, Novartis, Regeneron, Sanofi-Aventis, Sanofi-Genzyme, StallergenesGreer, UCB pharma, Uriach Pharma, Valeas, and ViborPharma. F. Blasi reports grants and personal fees from AstraZeneca, Chiesi, GSK, Pfizer and Insmed; grants from Bayer; and personal fees from Guidotti, Grifols, Menarini, Mundipharma, Novartis, and Zambon, outside the submitted work. P. Paggiaro reports grants and personal fees from AstraZeneca, Chiesi, Novartis, and Sanofi; and personal fees from GlaxoSmithKline, Guidotti, and Mundipharma, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2021",

doi = "10.1016/j.jaip.2021.04.011",

language = "English",

volume = "9",

pages = "2920--2922.e2",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "American Academy of Allergy, Asthma and Immunology",

number = "7",

}

TY - JOUR

T1 - Aspergillus-related diseases in a cohort of patients with severe asthma

T2 - A SANI single-center report

AU - Solidoro, Paolo

AU - Nicola, Stefania

AU - Ridolfi, Irene

AU - Bucca, Caterina

AU - Heffler, Enrico

AU - Bagnasco, Diego

AU - Canonica, Giorgio Walter

AU - Blasi, Francesco

AU - Paggiaro, Pierluigi

AU - Rolla, Giovanni

AU - Brussino, Luisa

N1 - Funding Information: Conflicts of interest: E. Heffler reports participation to advisory boards and personal fees from AstraZeneca, Sanofi, GSK, Novartis, Circassia, Nestl? Purina, Boheringer Ingheleim, and Valeas, outside the submitted work. G. W. Canonica reports grants as well as lecture or advisory board fees from A. Menarini, Alk-Abello, Allergy Therapeutics, AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, Glaxo Smith Kline, Hal Allergy, Mylan, Merck, Mundipharma, Novartis, Regeneron, Sanofi-Aventis, Sanofi-Genzyme, StallergenesGreer, UCB pharma, Uriach Pharma, Valeas, and ViborPharma. F. Blasi reports grants and personal fees from AstraZeneca, Chiesi, GSK, Pfizer and Insmed; grants from Bayer; and personal fees from Guidotti, Grifols, Menarini, Mundipharma, Novartis, and Zambon, outside the submitted work. P. Paggiaro reports grants and personal fees from AstraZeneca, Chiesi, Novartis, and Sanofi; and personal fees from GlaxoSmithKline, Guidotti, and Mundipharma, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85106372715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106372715&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2021.04.011

DO - 10.1016/j.jaip.2021.04.011

M3 - Article

C2 - 33892172

AN - SCOPUS:85106372715

VL - 9

SP - 2920-2922.e2

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 7

ER -

Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this